Pascal and Francis Bibliographic Databases


Search results

Your search

au.\*:("THAMM, Douglas H")

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 13 of 13

  • Page / 1

Selection :

  • and

Phase I Pharmacokinetic and Pharmacodynamic Evaluation of Combined Valproic Acid/Doxorubicin Treatment in Dogs with Spontaneous CancerWITTENBURG, Luke A; GUSTAFSON, Daniel L; THAMM, Douglas H et al.Clinical cancer research (Print). 2010, Vol 16, Num 19, pp 4832-4842, issn 1078-0432, 11 p.Article

The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicinWITTENBURG, Luke A; BISSON, Liam; ROSE, Barbara J et al.Cancer chemotherapy and pharmacology. 2011, Vol 67, Num 1, pp 83-92, issn 0344-5704, 10 p.Article

Polymer-Modified Gadolinium Metal-Organic Framework Nanoparticles Used as Multifunctional Nanomedicines for the Targeted Imaging and Treatment of CancerROWE, Misty D; THAMM, Douglas H; KRAFT, Susan L et al.Biomacromolecules. 2009, Vol 10, Num 4, pp 983-993, issn 1525-7797, 11 p.Article

Optofluidic Intracavity Spectroscopy of Canine HemangiosarcomaWEINA WANG; KISKER, David W; THAMM, Douglas H et al.IEEE transactions on biomedical engineering. 2011, Vol 58, Num 4, pp 853-860, issn 0018-9294, 8 p.Article

Assessment of GS-9219 in a Pet Dog Model of Non-Hodgkin's LymphomaVAIL, David M; THAMM, Douglas H; JERAJ, Robert et al.Clinical cancer research (Print). 2009, Vol 15, Num 10, pp 3503-3510, issn 1078-0432, 8 p.Article

Expression and Function of Survivin in Canine OsteosarcomaSHOENEMAN, Jenette K; EHRHART, E. J; EICKHOFF, Jens C et al.Cancer research (Chicago, Ill.). 2012, Vol 72, Num 1, pp 249-259, issn 0008-5472, 11 p.Article

Intralesional lipid-complexed cytokine/superantigen immunogene therapy for spontaneous canine tumorsTHAMM, Douglas H; KURZMAN, Ilene D; MACEWEN, E. Gregory et al.Cancer immunology and immunotherapy. 2003, Vol 52, Num 8, pp 473-480, issn 0340-7004, 8 p.Article

Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia : Phase I evaluationTHAMM, Douglas H; KURZMAN, Ilene D; KING, Ivan et al.Clinical cancer research. 2005, Vol 11, Num 13, pp 4827-4834, issn 1078-0432, 8 p.Article

Tuning the Magnetic Resonance Imaging Properties of Positive Contrast Agent Nanoparticles by Surface Modification with RAFT PolymersROWE, Misty D; CHANG, Chia-Chih; THAMM, Douglas H et al.Langmuir. 2009, Vol 25, Num 16, pp 9487-9499, issn 0743-7463, 13 p.Article

Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcomaKATAYAMA, Rieko; HUELSMEYER, Michael K; MARR, Amanda K et al.Cancer chemotherapy and pharmacology. 2004, Vol 54, Num 1, pp 25-33, issn 0344-5704, 9 p.Article

Preclinical study of dolastatin-10 in dogs with spontaneous neoplasiaTHAMM, Douglas H; MACEWEN, E. Gregory; PHILLIPS, Brenda S et al.Cancer chemotherapy and pharmacology. 2002, Vol 49, Num 3, pp 251-255, issn 0344-5704Article

Chronic bacterial osteomyelitis suppression of tumor growth requires innate immune responsesSOTTNIK, Joseph L; U'REN, Lance W; THAMM, Douglas H et al.Cancer immunology and immunotherapy. 2010, Vol 59, Num 3, pp 367-378, issn 0340-7004, 12 p.Article

Preclinical Investigation of PEGylated Tumor Necrosis Factor α in Dogs with Spontaneous Tumors: Phase I EvaluationTHAMM, Douglas H; KURZMAN, Ilene D; CLARK, Mike A et al.Clinical cancer research (Print). 2010, Vol 16, Num 5, pp 1498-1508, issn 1078-0432, 11 p.Article

  • Page / 1